Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially
infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically
engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium
iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian
cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast
cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical
data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results
of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm
vector developments and creative strategies for future translational steps.
Keywords: Cancer gene therapy, measles virus clinical trials, MV-CEA, MV-NIS, oncolytic measles, virotherapy.
Rights & PermissionsPrintExport